SCHEMBL3435874

SCHEMBL3435874

O=C(O)c1csc(Cc2cc(Cl)cc(Cl)c2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 5/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
MMP1 P03956 1/20 0.48
MMP2 P08253 1/20 0.48
MMP9 P14780 1/20 0.48
MMP13 P45452 1/20 0.48
NPC1 O15118 2/20 0.44
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.43
RECQL P46063 1/20 0.43
HPGD P15428 1/20 0.43
PTGER1 P34995 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327057 0.84 LMNA (0.65) LMNARAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3435197 0.80 MAPT (0.54) LMNARAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL1977126 0.79 HDAC1 (0.72) LMNARAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL1659564 0.78 CACNA1G (0.60) LMNARAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL4724594 0.76 PTGER1 (0.52) LMNARAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL2497828 0.74 MMP1 (0.53) LMNARAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3597949 0.74 MMP1 (0.53) ALDH1A1L3MBTL1HDAC1HDAC8HDAC6
SCHEMBL5215851 0.74 CDK5 (0.54) LMNARAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL5345784 0.74 MMP1 (0.47) LMNARAB9ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL16377465 0.73 MMP1 (0.49) ALDH1A1L3MBTL1HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304547-B2 Azolecarboxamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2012-11-06 US disclosed
US-8304547-B2 Azolecarboxamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2012-11-06 US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 US disclosed
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 EP disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF TRPV1, FGFR3, GPR17 LMNA 4603/4885RAB9A 4223/4885SMN1; SMN2 3213/4885
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 LMNA 4712/4885RAB9A 4401/4885SMN1; SMN2 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.